Patents Assigned to Beta Bionics, Inc.
  • Patent number: 11594314
    Abstract: Blood glucose control systems are disclosed. A blood glucose control system can receive a glucose level signal from a glucose sensor operatively coupled to a subject. The system can decode encoded data of the glucose level signal to obtain the glucose level of the subject and the indication of the glucose trend. The system can automatically calculate the dose control signal using a control algorithm configured to calculate regular correction boluses of glucose control agent in response to at least the glucose level of the subject. The system can select a dose control signal encoding profile from a plurality of dose control signal encoding profiles and, based on the dose control signal encoding profile, encode the dose control signal such that the pump controller can read the dose control signal. The system can transmit an encoded dose control signal to the pump controller.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: February 28, 2023
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Patent number: 11587664
    Abstract: Systems and methods are disclosed herein for providing a configuration code for customizing a glucose level control system for at least an initial period. The configuration code can be based on one or more dosing parameters from a tracked medicament therapy administered to a subject over a tracking period by the glucose level control system. The configuration code includes encoded dosing parameters including a correction dosing parameter based on at least some of the correction boluses of medicament administered during the tracking period, a food intake dosing parameter comprising an indication of a food intake bolus size of medicament based on one or more food intake boluses provided during the tracking period, and a basal dosing parameter based on at least some of the basal doses of medicament administered during the tracking period.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: February 21, 2023
    Assignee: Beta Bionics, Inc.
    Inventors: Firas H. El-Khatib, Himanshu Patel, Edward R. Damiano, Michael J. Rosinko
  • Patent number: 11581080
    Abstract: Ambulatory medical devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and devices can transmit a request to modify blood glucose control therapy delivered to a subject. The request can be transmitted via a voice-activated control system, the ambulatory medicament pump can include a medicament reservoir, a pump controller, a wireless data interface, and/or other elements. The device can receive an indication that the request to modify therapy is approved and, in response to the indication that the request to modify the blood glucose control therapy is approved, instruct the pump controller to modify the blood glucose control therapy delivered to the subject.
    Type: Grant
    Filed: March 31, 2022
    Date of Patent: February 14, 2023
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Firas H. El-Khatib, John R. Costik
  • Patent number: 11571507
    Abstract: Certain embodiments provide multi-medicament or single medicament infusion systems for preventing the cross-channeling or improper delivery of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The medicament cartridges may be sized and shaped differently such that the medicament reservoirs can only be inserted into the pump under selected configurations.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: February 7, 2023
    Assignee: Beta Bionics, Inc.
    Inventors: Edward R. Damiano, David Matthew Henderson, Bryan Dale Knodel, Michael J. Rosinko, Justin P. Brown, Todd S. Ray, Mads Henrik Dall, David Chi-Wai Lim
  • Patent number: 11565041
    Abstract: Ambulatory medicament devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and methods can implement one or more features that improve the user experience, by modifying delivery of therapy to a subject after determining that a possible occlusion exists in a medicament delivery system, monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device and annunciating alarm condition when necessary, selectively muting alarm annunciations while a Do Not Disturb mode is activated, implementing various power saving modes to save power, controlling operation of the device and medicament delivery based on the user gesture controls, and controlling medicament delivery based on a condition of the ambulatory medicament device.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: January 31, 2023
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Justin P. Brown
  • Patent number: 11529466
    Abstract: Ambulatory medical devices, which includes ambulatory medicament pumps, and blood glucose control systems that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and devices can implement one or more features that improve the user experience, such as prompting and/or facilitating the user to order additional infusion sets, sensors, and/or other components to facilitate treatment.
    Type: Grant
    Filed: March 29, 2022
    Date of Patent: December 20, 2022
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Patent number: 11515027
    Abstract: Ambulatory medical devices, which includes ambulatory medicament pumps, and blood glucose control systems that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and devices can implement one or more features that improve the user experience, such as prompting and/or facilitating the user to order additional infusion sets, sensors, and/or other components to facilitate treatment.
    Type: Grant
    Filed: March 24, 2022
    Date of Patent: November 29, 2022
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Patent number: 11497849
    Abstract: Ambulatory medicament devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and methods can implement one or more features that improve the user experience, by modifying delivery of therapy to a subject after determining that a possible occlusion exists in a medicament delivery system, monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device and annunciating alarm condition when necessary, selectively muting alarm annunciations while a Do Not Disturb mode is activated, implementing various power saving modes to save power, controlling operation of the device and medicament delivery based on the user gesture controls, and controlling medicament delivery based on a condition of the ambulatory medicament device.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: November 15, 2022
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Justin P. Brown
  • Patent number: 11497852
    Abstract: Ambulatory medicament devices that provide therapy to a subject, such as blood glucose control, are disclosed. Disclosed systems and methods can implement one or more features that improve the user experience, by modifying delivery of therapy to a subject after determining that a possible occlusion exists in a medicament delivery system, monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device and annunciating alarm condition when necessary, selectively muting alarm annunciations while a Do Not Disturb mode is activated, implementing various power saving modes to save power, controlling operation of the device and medicament delivery based on the user gesture controls, and controlling medicament delivery based on a condition of the ambulatory medicament device.
    Type: Grant
    Filed: March 2, 2022
    Date of Patent: November 15, 2022
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Justin P. Brown
  • Patent number: 11278661
    Abstract: Certain embodiments provide multi-medicament infusion systems for preventing the cross-channeling of medicaments. The system may include one or more of an infusion pump, medicament cartridges, cartridge connectors, a multi-channel fluid conduit, and an infusion set. The infusion pump can have an inductively chargeable battery assembly that can be charged by an inductive charging pad.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: March 22, 2022
    Assignee: BETA BIONICS, INC.
    Inventors: David Matthew Henderson, Todd S. Ray, Michael J. Rosinko, Bryan Dale Knodel
  • Patent number: 11260174
    Abstract: Systems and methods presented herein relate to managing ambulatory medical device data access. A computing system of a networked computing environment can establish a direct end-to-end data connection to an ambulatory medical device via a wireless wide area network. A public key of the computing system may be transmitted to the ambulatory medical device permitting the ambulatory medical device to encrypt data to be transmitted to the computing system. The computing system may receive, via the direct end-to-end data connection, encrypted data from the ambulatory medical device, and upon decrypting the data can generate a therapy report based at least in part on the therapy data. This therapy report may include time-series therapy data relating to the therapy delivered by the ambulatory medical device over a particular time period. The computing system can restrict access to the therapy report to authorized users.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: March 1, 2022
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, Michael J. Rosinko
  • Patent number: 11154656
    Abstract: An automated blood glucose control system can provide automatic delivery of glucose control therapy to a subject and receive information about manual glucose control therapy provided to the subject. The automated blood glucose control system can indicate an amount of a bolus of medicament via a control algorithm configured to control blood glucose level in the subject. The automated blood glucose control system can indicate an amount of a manual bolus of medicament, which can be used to model a diminishment of the medicament in the subject over time based at least in part on the manual bolus of medicament.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 26, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Firas H. El-Khatib, Edward R. Damiano, Edward B. Raskin, David Chi-Wai Lim, Michael J. Rosinko, John R. Costik
  • Patent number: 11135365
    Abstract: An ambulatory medicament device can generate a dose control signal for delivery of medicament to a subject and secure at least some functionality of a user interface of the ambulatory medicament device. The ambulatory medicament device can have a locked state that restricts modification of at least one control parameter. The ambulatory medicament device can have an unlocked state that allows modification of at least one control parameter. The ambulatory medicament device can accept a user input of a security code that is validated against a passcode to enter from the locked state to the unlocked state.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib
  • Patent number: 11135363
    Abstract: Systems and methods relate to an ambulatory medicament device that can generate a dose control signal to cause a medicament pump to infuse medicament into a subject. The system can analyze status to determine whether an alarm condition for the ambulatory medicament device or for a subject is already present in a list of pending alarm conditions. If the alarm is not present, the system can determine a severity level of the alarm condition from among a plurality of severity levels and annunciate the alarm condition using one or more annunciation patterns selected based on the severity level of the alarm condition for the medicament device or for the subject. The system may maintain an indication of the alarm condition on the list of pending alarm conditions until the alarm condition is resolved.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, David Chi-Wai Lim, Edward R. Damiano, Firas H. El-Khatib, Himanshu Patel
  • Patent number: 11135366
    Abstract: An ambulatory medical device can detect a device condition and determine if the device condition satisfies a set of normal operating parameters. If the normal operating parameters are not satisfied, the ambulatory medical device can determine if the device condition stratifies a set of minimum operating parameters. If the minimum operating parameters are satisfied, the ambulatory medical device can maintain a delivery of therapy to a subject and generate an alert based on the device condition.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Himanshu Patel, Edward R. Damiano, Firas H. El-Khatib, David Chi-Wai Lim
  • Patent number: 11135364
    Abstract: Systems and methods are disclosed herein for monitoring the status of an ambulatory medical device and the health condition of a subject that receives therapy from the ambulatory medical device. The ambulatory medical device can have a touchscreen display user interface to receive input signals from a user and display alarm conditions associated with the status of an ambulatory medical device or health condition of a subject. The disclosed methods and systems can determine whether status information received from a monitoring system interface satisfies an alarm condition for the ambulatory medicament device or for the subject. If the status information satisfies an alarm condition, the touchscreen user interface can display one or more alarm status indicators corresponding to the alarm condition. The user can activate a therapy change interface on the touchscreen display and modify a control parameter of the ambulatory medical device that controls the therapy delivery to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: October 5, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11129938
    Abstract: Systems and methods are disclosed herein for updating an application controlling an ambulatory medical device such that application updates can be identified, downloaded and installed without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system configured to host the application update, and download the application update. The disclosed systems and methods can determine an execution time of an installation and install the downloaded application update without interrupting therapy provided by the ambulatory medical device to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 28, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Himanshu Patel, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11123486
    Abstract: Systems and methods are disclosed herein for switching control of an ambulatory medical device from an application executing on the ambulatory medical device to a safe version or a new version of the application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device can maintain copies of a safe version and a new version of the application. The disclosed systems and methods can execute the new version, while the prior version of the application continues to execute, determine whether a minimum set of operating conditions are satisfied by the new version, and switch control of the ambulatory medical device from the prior version to the new version. The systems and methods can also automatically revert to the safe version of the application case the current version is malfunctioning without interrupting therapy provided to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 21, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, Himanshu Patel, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11123485
    Abstract: Systems and methods are disclosed herein for switching an application executing on an ambulatory medical device to a new application without interrupting therapy provided by the ambulatory medical device to a subject. The ambulatory medical device may receive an indication that an update to an application executing on the ambulatory insulin pump is available, establish a communication connection to a host computing system, download and install the application update, while a prior version of the application continues to run. The disclosed systems and methods can confirm successful installation of the application update on the ambulatory medical device and switch control of the ambulatory medical device from the prior version to the new version of the application without interrupting therapy provided to the subject.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 21, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Himanshu Patel, Michael J. Rosinko, Edward R. Damiano, David Chi-Wai Lim, Firas H. El-Khatib, John R. Costik, Justin P. Brown, Bryan Dale Knodel
  • Patent number: 11116902
    Abstract: A blood glucose control system is configured to modify therapy provided to a subject. The system can cause first therapy to be delivered by the blood glucose control system to a subject during a first therapy period. The first therapy can be delivered based at least in part on a first value of a control parameter used by a control algorithm to generate a dose control signal. The system can determine a first effect corresponding at least in part to the first therapy and autonomously generate a second value of the control parameter. The system can cause second therapy to be delivered by the blood glucose control system to the subject during a second therapy period, wherein the second therapy is delivered based at least in part on the second value of the control parameter.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: September 14, 2021
    Assignee: Beta Bionics, Inc.
    Inventors: Firas H. El-Khatib, Edward R. Damiano